Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma

Trial Profile

Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Vandetanib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
    • 21 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
    • 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top